1. (currently amended) An oral matrix pharmaceutical composition comprising doxazosin or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer or mixture thereof, a low viscosity release retarding agent, ~~and~~ a high viscosity release retarding agent, and one or more solubility enhancers.

2. (original) The composition of claim 1, wherein the release retarding agents include one or more of cellulose derivatives, acrylic acid or methacrylate polymers/copolymers, gums, vinyl alcohol or vinylpyrrolidone based polymers, block copolymers, or polyethylene oxide.

3. (original) The composition of claim 2, wherein the cellulose derivatives comprise one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, or methylcellulose.

4. (original) The composition of claim 1, wherein the low viscosity release retarding agent comprises between about 5% to about 40% w/w of the composition.

5. (original) The composition of claim 1, wherein the low viscosity release retarding agent comprises between about 8% to about 25% w/w of the composition.

6. (original) The composition of claim 1, wherein the high viscosity release retarding agent comprises between about 5% to about 40% w/w of the composition.

7. (original) The composition of claim 1, wherein the high viscosity release retarding agent comprises between about 8% to about 20% w/w of the composition.

8. (cancelled)

9. (original) The composition of claim 1, wherein the one or more solubility enhancers comprises one or more of polyethylene glycols, surfactants, propylene glycol, glycerol, mono-alcohols, higher alcohols, DMSO, dimethylformamide, N, N-dimethylacetamide, 2-pyrrolidone; N-(2-hydroxyethyl) pyrrolidone, N-methylpyrrolidone, 1-dodecylazacycloheptan-2-one and other n-substituted-alkyl-azacycloalkyl- -2-ones.

10. (original) The composition of claim 1, further comprising one or more pharmaceutically acceptable excipients.

11. (original) The composition of claim 10, wherein the one or more pharmaceutically acceptable excipients comprise one or more of binders, diluents and lubricant/glidants.

12. (original) The composition of claim 1, wherein the composition is the form of tablets, capsules, pellets, granules or any other dosage forms suitable for oral administration.

13. (original) The composition of claim 1, wherein the composition releases the doxazosin over a period of about 12 hours to about 24 hours.

14. (currently amended) ~~An~~ The oral matrix pharmaceutical composition according to claim 1, further comprising ~~doxazosin or its salt, solvate hydrate, enantiomers or mixture thereof,~~ about 5% to about 40% w/w of hydroxypropylmethyl cellulose of high viscosity as the high viscosity release retarding agent, about 5% to about 40% w/w of hydroxypropyl methylcellulose of low viscosity as the low viscosity release retarding agent, about 2% to about 20% w/w of polyethylene glycol, about 15% to about 50% w/w of lactose, about 10% to about 50% w/w of microcrystalline cellulose, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.

15. (currently amended) ~~An~~ The oral matrix pharmaceutical composition according to claim 14, further comprising ~~doxazosin or a salt, solvate, hydrate, enantiomer or mixture thereof,~~ about 8% to about 20% w/w of hydroxypropylmethyl cellulose of high viscosity, about 8% to about 25% w/w of hydroxypropyl methylcellulose of low viscosity, about 5% to about 10% w/w of polyethylene glycol, about 20% to about 40% w/w of lactose, about 20% to about 40% w/w of microcrystalline cellulose, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.

16. (currently amended) ~~An~~ The oral matrix pharmaceutical composition according to claim 1, further comprising ~~doxazosin or a salt, solvate, hydrate, enantiomer or mixture thereof,~~ about 5% to about 40% w/w of hydroxypropyl methylcellulose of

high viscosity as the high viscosity release retarding agent, about 5% to about 40% w/w of hydroxypropyl methylcellulose of low viscosity as the low viscosity release retarding agent, about 1% to about 20% w/w of sodium alginate and alginic acid, about 5% to about 20% of Eudragit EPO, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.

17. (currently amended) ~~An~~ The oral matrix pharmaceutical composition according to claim 16, further comprising ~~doxazosin or a salt, solvate, hydrate, enantiomer or mixture thereof,~~ about 8% to about 20% w/w of hydroxypropyl methylcellulose of high viscosity as the high viscosity release retarding agent, about 10% to about 25% w/w of hydroxypropyl methylcellulose of low viscosity as the low viscosity release retarding agent, about 2% to about 10% w/w of sodium alginate and alginic acid, about 6% to about 10% w/w of Eudragit EPO, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.

18. (currently amended) A method of treating one or more of hypertension, urinary outflow obstruction and symptoms associated with benign protastic hyperplasia in a patient in need thereof, the method comprising administering an oral matrix pharmaceutical composition comprising doxazosin or a pharmaceutically acceptable salt thereof, a low viscosity release retarding agent, ~~and~~ a high viscosity release retarding agent, and one or more solubility enhancers.